Unlock the Editor’s Digest free of charge
Roula Khalaf, Editor of the FT, selects her favorite tales on this weekly publication.
GSK is nearing a $1bn deal to purchase a US biotech growing a remedy for uncommon gastrointestinal tumours, because the UK drugmaker races to increase its oncology enterprise.
The UK group is in superior talks to purchase privately owned biotech IDRx, which has enterprise capital companies Andreessen Horowitz and RA Capital in addition to non-public fairness large Blackstone amongst its backers, in keeping with folks near the discussions. The biotech, which was final valued at $430mn at a funding spherical in August, might be offered for as a lot as $1bn, the folks added.
The sale is prone to be introduced forward of the JPMorgan healthcare convention in San Francisco subsequent week, the place a flurry of biotech offers are sometimes unveiled, the folks stated, however they added that negotiations have been ongoing and the deal may fall via or one other purchaser may emerge.
GSK declined to remark. IDRx didn’t instantly reply to request for remark.
IDRx is conducting early-stage trials of its focused remedy for sufferers with a sort of most cancers referred to as gastrointestinal stromal tumour, or Gist, which impacts between 4,000 and 6,000 folks every year within the US.
The accessible therapies for Gist will not be very efficient due to resistance mutations within the most cancers in 80 per cent of instances. IDRx’s experimental drug has proven early indicators of addressing this drawback.
In a phase-one trial on sufferers that had already tried two different therapies that had stopped working, the IDRx drug stopped their tumours from rising for 12.9 months.
An acquisition of IDRx would assist GSK to increase its oncology enterprise, which is smaller than that of rivals similar to Merck and AstraZeneca.
The UK drugmaker has prioritised bolt-on acquisitions of about $1bn, partly as a result of it has a smaller offers finances than lots of its friends. However is it additionally in step with present trade traits: in 2024, most pharma teams eschewed bigger offers in favour of smaller acquisitions.
Gross sales of most cancers medication at GSK elevated 94 per cent 12 months on 12 months to greater than $1bn within the first three quarters of 2024. This included a contribution from the drug Ojjaara, which the corporate acquired as a part of its $1.7bn buy of Sierra Oncology in 2022.
This 12 months, GSK is hoping to revive one other drug, Blenrep, for a sort of blood most cancers, to the US market, after it voluntarily withdrew the remedy in 2022 as a result of it didn’t beat rivals in a trial.
GSK introduced new outcomes for the drug in November, reporting “statistically vital and clinically significant” results for Blenrep when it was used with one other established remedy.
In oncology, GSK has been constructing a portfolio of “antibody drug conjugates”, a brand new kind of chemotherapy that goals to kill cancerous cells whereas sparing wholesome ones. Late final 12 months, it signed a deal price as much as $975mn with Shanghai-based Duality Bio for an antibody drug conjugate to deal with gastrointestinal most cancers, its third ADC deal in 18 months.
